HALOZYME THERAPEUTICS, INC.

(HALO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
38.2(c) 38.58(c) 39.04(c) 40.42(c) 41.69(c) Last
1 163 211 1 495 897 1 009 118 1 101 626 1 318 723 Volume
+2.28% +0.99% +1.19% +3.53% +3.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 558 M - -
Net income 2022 280 M - -
Net Debt 2022 172 M - -
P/E ratio 2022 20,4x
Yield 2022 -
Sales 2023 710 M - -
Net income 2023 379 M - -
Net cash position 2023 157 M - -
P/E ratio 2023 15,2x
Yield 2023 -
Capitalization 5 744 M 5 744 M -
EV / Sales 2022 10,6x
EV / Sales 2023 7,87x
Nbr of Employees 145
Free-Float 98,8%
More Financials
Company
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaboratorsÔÇÖ... 
More about the company
Ratings of Halozyme Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about HALOZYME THERAPEUTICS, INC.
05/12Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
MT
05/12Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
PR
05/11JMP Securities Raises Halozyme Therapeutics Price Target to $58 From $55, Maintains Mar..
MT
05/10TRANSCRIPT : Halozyme Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/10Halozyme Therapeutics' Q1 Non-GAAP Earnings, Revenue Rise; Issues Full Year 2022 Guidan..
MT
05/10Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $117.3M, vs. Street Est of..
MT
05/10HALOZYME THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/10Halozyme Reports First Quarter 2022 Results
PR
05/10Halozyme Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/10Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022
CI
05/06HALOZYME THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
05/03Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
PR
04/26Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares
MT
04/26Halozyme commences tender offer for all outstanding shares of common stock of antares p..
PR
More news
News in other languages on HALOZYME THERAPEUTICS, INC.
05/12Halozyme déclare que la période d'attente de la loi antitrust a expiré pour l'acquisiti..
05/10Earnings Flash (HALO) HALOZYME THERAPEUTICS affiche un chiffre d'affaires de 117,3 mill..
05/10Halozyme Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
05/10Halozyme Therapeutics, Inc. réitère ses prévisions de bénéfices pour l'année 2022
04/26Halozyme Therapeutics propose une offre publique d'achat en espèces pour acquérir les a..
More news
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
More recommendations
Chart HALOZYME THERAPEUTICS, INC.
Duration : Period :
Halozyme Therapeutics, Inc. Technical Analysis Chart | HALO | US40637H1095 | MarketScreener
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 41,69 $
Average target price 49,13 $
Spread / Average Target 17,8%
EPS Revisions
Managers and Directors
Helen I. Torley President, Chief Executive Officer & Director
Nicole LaBrosse Executive Director & Controller
Connie L. Matsui Chairman
Michael J. LaBarre Chief Technical Officer & Senior Vice President
Steve Knowles Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HALOZYME THERAPEUTICS, INC.3.68%5 569
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601